Patents by Inventor Paul E. Kennedy

Paul E. Kennedy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200332199
    Abstract: The disclosed invention relates to a method for restarting a synthesis gas conversion process which has stopped. The synthesis gas conversion process may be conducted in a conventional reactor or a microchannel reactor. The synthesis gas conversion process may comprise a process for converting synthesis gas to methane, methanol or dimethyl ether. The synthesis gas conversion process may be a Fischer-Tropsch process.
    Type: Application
    Filed: July 1, 2020
    Publication date: October 22, 2020
    Inventors: Roger A. Harris, Soumitra R. Deshmukh, Paul E. Kennedy, Robert Dwayne Litt, Lucas D. Schrader, Andre P. Steynberg, Steven T. Perry
  • Patent number: 10752843
    Abstract: The disclosed invention relates to a method for restarting a synthesis gas conversion process which has stopped. The synthesis gas conversion process may be conducted in a conventional reactor or a microchannel reactor. The synthesis gas conversion process may comprise a process for converting synthesis gas to methane, methanol or dimethyl ether. The synthesis gas conversion process may be a Fischer-Tropsch process.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: August 25, 2020
    Assignee: Velocys, Inc.
    Inventors: Roger A. Harris, Soumitra R. Deshmukh, Paul E. Kennedy, Robert Dwayne Litt, Lucas D. Schrader, Andre P. Steynberg, Steven T. Perry
  • Publication number: 20190345394
    Abstract: The disclosed invention relates to a method for restarting a synthesis gas conversion process which has stopped. The synthesis gas conversion process may be conducted in a conventional reactor or a microchannel reactor. The synthesis gas conversion process may comprise a process for converting synthesis gas to methane, methanol or dimethyl ether. The synthesis gas conversion process may be a Fischer-Tropsch process.
    Type: Application
    Filed: July 2, 2019
    Publication date: November 14, 2019
    Inventors: Roger A. Harris, Soumitra R. Deshmukh, Paul E. Kennedy, Robert Dwayne Litt, Lucas D. Schrader, Andre P. Steynberg, Steven T. Perry
  • Patent number: 10358604
    Abstract: The disclosed invention relates to a method for restarting a synthesis gas conversion process which has stopped. The synthesis gas conversion process may be conducted in a conventional reactor or a microchannel reactor. The synthesis gas conversion process may comprise a process for converting synthesis gas to methane, methanol or dimethyl ether. The synthesis gas conversion process may be a Fischer-Tropsch process.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: July 23, 2019
    Assignee: Velocys, Inc.
    Inventors: Roger A. Harris, Deshmukh R. Soumitra, Paul E. Kennedy, Robert Dwayne Litt, Lucas D. Schrader, Andre P. Steynberg, Steven T. Perry
  • Publication number: 20160362611
    Abstract: The disclosed invention relates to a method for restarting a synthesis gas conversion process which has stopped. The synthesis gas conversion process may be conducted in a conventional reactor or a microchannel reactor. The synthesis gas conversion process may comprise a process for converting synthesis gas to methane, methanol or dimethyl ether. The synthesis gas conversion process may be a Fischer-Tropsch process.
    Type: Application
    Filed: July 13, 2016
    Publication date: December 15, 2016
    Inventors: Roger A. Harris, Deshmukh R. Soumitra, Paul E. Kennedy, Robert Dwayne Litt, Lucas D. Schrader, Andre P. Steynberg, Steven T. Perry
  • Publication number: 20080241167
    Abstract: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.
    Type: Application
    Filed: March 7, 2008
    Publication date: October 2, 2008
    Inventors: Christophe Combadiere, Yu Feng, Ghalib Alkhatib, Edward A. Berger, Philip M. Murphy, Christopher C. Broder, Paul E. Kennedy
  • Patent number: 7151087
    Abstract: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: December 19, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Resources
    Inventors: Christophe Combadiere, Yu Feng, Ghalib Alkhatib, Edward A. Berger, Philip M. Murphy, Christopher C. Broder, Paul E. Kennedy
  • Patent number: 6989135
    Abstract: A Fischer-Tropsch-based hydrocarbon conversion process involves compressing air in a compressor section of a gas turbine, delivering a portion of the compressed air to a combustor of the gas turbine, delivering a portion of the compressed air to a Fischer-Tropsch hydrocarbon conversion unit, extracting thermal energy from the combustor and delivering it to the Fischer-Tropsch hydrocarbon conversion unit, converting light hydrocarbons into heavier hydrocarbons in the Fischer-Tropsch hydrocarbon conversion unit, and delivering combustion gases from the combustor to an expansion section of the gas turbine. A heat recovery steam generator (HRSG) may also be used to harness waste heat from the expansion section. A conversion system for converting light hydrocarbons into heavier hydrocarbons includes a turbine from which heat energy is removed and used to assist in converting hydrocarbons and whereby greater throughput of the turbine is possible.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: January 24, 2006
    Assignee: Syntroleum Corporation
    Inventor: Paul E. Kennedy
  • Publication number: 20040259785
    Abstract: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.
    Type: Application
    Filed: October 31, 2003
    Publication date: December 23, 2004
    Applicant: The Govt. of the USA, as represented by the Secretary of the Dept. of Health & Human Services
    Inventors: Christophe Combadiere, Yu Feng, Ghalib Alkhatib, Edward A. Berger, Philip M. Murphy, Christopher C. Broder, Paul E. Kennedy
  • Publication number: 20030195348
    Abstract: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.
    Type: Application
    Filed: May 15, 2003
    Publication date: October 16, 2003
    Applicants: The United States of America, represented by the Secretary,, Department of Health and Human Services
    Inventors: Christophe Combadiere, Yu Feng, Ghalib Alkhatib, Edward A. Berger, Philip M. Murphy, Christopher C. Broder, Paul E. Kennedy
  • Publication number: 20010044476
    Abstract: A Fischer-Tropsch-based hydrocarbon conversion process involves compressing air in a compressor section of a gas turbine, delivering a portion of the compressed air to a combustor of the gas turbine, delivering a portion of the compressed air to a Fischer-Tropsch hydrocarbon conversion unit, extracting thermal energy from the combustor and delivering it to the Fischer-Tropsch hydrocarbon conversion unit, converting light hydrocarbons into heavier hydrocarbons in the Fischer-Tropsch hydrocarbon conversion unit, and delivering combustion gases from the combustor to an expansion section of the gas turbine. A heat recovery steam generator (HRSG) may also be used to harness waste heat from the expansion section. A conversion system for converting light hydrocarbons into heavier hydrocarbons includes a turbine from which heat energy is removed and used to assist in converting hydrocarbons and whereby greater throughput of the turbine is possible.
    Type: Application
    Filed: June 8, 2001
    Publication date: November 22, 2001
    Inventor: Paul E. Kennedy
  • Patent number: 6265453
    Abstract: A Fischer-Tropsch-based hydrocarbon conversion process involves compressing air in a compressor section of a gas turbine, delivering a portion of the compressed air to a combustor of the gas turbine, delivering a portion of the compressed air to a Fischer-Tropsch hydrocarbon conversion unit, extracting thermal energy from the combustor and delivering it to the Fischer-Tropsch hydrocarbon conversion unit, converting light hydrocarbons into heavier hydrocarbons in the Fischer-Tropsch hydrocarbon conversion unit, and delivering combustion gases from the combustor to an expansion section of the gas turbine. A heat recovery steam generator (HRSG) may also be used to harness waste heat from the expansion section. A conversion system for converting light hydrocarbons into heavier hydrocarbons includes a turbine from which heat energy is removed and used to assist in converting hydrocarbons and whereby greater throughput of the turbine is possible.
    Type: Grant
    Filed: June 15, 2000
    Date of Patent: July 24, 2001
    Assignee: Syntroleum Corporation
    Inventor: Paul E. Kennedy
  • Patent number: 5591731
    Abstract: The present invention relates to a sterile, stable vacuum dried crystalline amifostine composition and, optionally, pharmaceutically acceptable excipient(s). Typically, the crystalline compositions of the present invention exhibit enhanced stability at temperatures ranging from about 4.degree. C. to about ambient temperature for a period of at least 2 years relative to existing solid vacuum dried amorphous amifostine preparations. The reconstituted compositions of the present invention are suitable for administration to humans as a radio- or chemoprotecting agent.
    Type: Grant
    Filed: February 16, 1995
    Date of Patent: January 7, 1997
    Assignee: U.S. Bioscience, Inc.
    Inventors: Paul E. Kennedy, Roger A. Rajewski, John M. Baldoni
  • Patent number: 5424471
    Abstract: The present invention relates to a sterile, stable vacuum dried crystalline amifostine composition and, optionally, pharmaceutically acceptable excipient(s). Typically, the crystalline compositions of the present invention exhibit enhanced stability at temperatures ranging from about 4.degree. C. to about ambient temperature for a period of at least 2 years relative to existing solid vacuum dried amorphous amifostine preparations. The reconstituted compositions of the present invention are suitable for administration to humans as a radio- or chemoprotecting agent.
    Type: Grant
    Filed: July 29, 1993
    Date of Patent: June 13, 1995
    Assignee: U.S. Bioscience, Inc.
    Inventors: Paul E. Kennedy, Roger A. Rajewski, John M. Baldoni
  • Patent number: 4887995
    Abstract: A method of treating a person for sickle cell anemia including administering to the patient's blood a therapeutically effective dosage of ethacrynic acid. The dosage may be administered to blood removed from the patient which blood after addition of the compound is restored to the patient or by other means such as orally.
    Type: Grant
    Filed: January 22, 1985
    Date of Patent: December 19, 1989
    Assignee: University of Pittsburgh
    Inventors: Donald J. Abraham, Paul E. Kennedy
  • Patent number: 4715868
    Abstract: A process for the recovery of hydrocarbon vapors from an air-hydrocarbon mixture wherein the inlet air-hydrocarbon mixture is passed to an absorber vessel in which is fed a vacuum flashed liquid hydrocarbon absorbent to produce an absorber overhead gas stream which is passed to a solid absorbent bed. Once saturated, the adsorbed hydrocarbon on the solid adsorbent bed is removed by liquid vacuum pump regeneration, separated from the pump liquid, and returned to the system for use. Hydrocarbon free air is vented from the solid adsorbent bed during the adsorption mode.
    Type: Grant
    Filed: September 22, 1986
    Date of Patent: December 29, 1987
    Assignee: McGill Incorporated
    Inventor: Paul E. Kennedy
  • Patent number: 4670028
    Abstract: A process for the recovery of hydrocarbon vapors from an air-hydrocarbon mixture expelled as a result of storage breathing or loading of a vented hydrocarbon vessel. An inlet air-hydrocarbon mixture is passed to a first absorber in which is fed a vacuum flashed liquid hydrocarbon absorbent to produce a first absorber overhead gas which is passed to a solid absorbent bed. Once saturated, the absorbed hydrocarbon on the solid absorbent is removed by vacuum regeneration, separated from liquid supplied by the liquid ring pump creating the vacuum, and passed to a second absorber vessel where fresh liquid hydrocarbon absorbent is contacted therewith to produce a second absorber overhead gas which is combined with the incoming inlet air-hydrocarbon mixture to pass therewith to the first absorber. Hydrocarbon free air is vented from the solid absorbent bed during the adsorption mode.
    Type: Grant
    Filed: July 1, 1985
    Date of Patent: June 2, 1987
    Assignee: McGill Incorporated
    Inventor: Paul E. Kennedy
  • Patent number: 4650803
    Abstract: Water soluble prodrugs of rapamycin are disclosed which are useful as components in injectable pharmaceutical formulations for the treatment of tumors in mammals.
    Type: Grant
    Filed: December 6, 1985
    Date of Patent: March 17, 1987
    Assignee: University of Kansas
    Inventors: Valentino J. Stella, Paul E. Kennedy